Ken Griffin Pliant Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 34,200 shares of PLRX stock, worth $415,188. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,200
Previous 26,500
29.06%
Holding current value
$415,188
Previous $394,000
6.85%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding PLRX
# of Institutions
158Shares Held
63.8MCall Options Held
481KPut Options Held
105K-
Deep Track Capital, LP Greenwich, CT5.97MShares$72.5 Million2.11% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$60.4 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.6MShares$55.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$41.7 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN3.4MShares$41.3 Million3.33% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $591M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...